Last reviewed · How we verify

Luteal support with estrogen + progesterone

Rabin Medical Center · FDA-approved active Small molecule

Estrogen and progesterone supplementation during the luteal phase supports endometrial development and maintains pregnancy viability in assisted reproductive cycles.

Estrogen and progesterone supplementation during the luteal phase supports endometrial development and maintains pregnancy viability in assisted reproductive cycles. Used for Luteal phase support in assisted reproductive technology (ART) cycles, Endometrial preparation and pregnancy support in IVF and embryo transfer.

At a glance

Generic nameLuteal support with estrogen + progesterone
SponsorRabin Medical Center
Drug classHormone replacement therapy
TargetProgesterone receptor (PR) and estrogen receptor (ER)
ModalitySmall molecule
Therapeutic areaReproductive Medicine / Fertility
PhaseFDA-approved

Mechanism of action

Luteal support replaces or augments the corpus luteum's natural hormone production after ovulation induction or egg retrieval. Progesterone prepares and maintains the endometrium for embryo implantation, while estrogen enhances endometrial receptivity and blood flow. This combination is used to optimize uterine conditions during the critical window following embryo transfer in in vitro fertilization (IVF) and other fertility treatments.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: